Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs
- 1 October 2003
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 307 (1) , 117-128
- https://doi.org/10.1124/jpet.103.054072
Abstract
In vitro metabolic studies revealed that along with UDP-glucuronosyltransferase (UGT) 1A1, the hepatic UGT1A9 and the extrahepatic UGT1A7 are involved in the biotransformation of the active and toxic metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38). Variant UGT1A1 and UGT1A7 alleles have been reported but the polymorphic nature of the UGT1A9 gene has not been revealed yet. To further clarify the molecular determinants of irinotecan-induced toxicity, we have identified and characterized the functionality of novel UGT1A9 polymorphisms and determined whether additional missense polymorphisms exist in UGT1A7. Using direct DNA sequencing, four single nucleotide polymorphisms (SNPs) were identified in the first exons of UGT1A7 and UGT1A9. One of the two amino acid substitutions found in the UGT1A9 gene, UGT1A9*3 (M33T), results in a dramatic decrease in SN-38 glucuronide formation, with 3.8% of the activity of the UGT1A9*1 allele. In turn, the glucuronidation of flavopiridol, an anticancer drug biotransformed predominantly by UGT1A9, remains unaffected, indicating a substrate-dependent impact of this variant. UGT1A9*3 is detected only in Caucasians and 4.4% of the population tested was found heterozygous (*1/*3). Two additional UGT1A7 SNPs were found exclusively in African-American subjects and generate five alleles (UGT1A7*5 to *9) when combined to the four known SNPs present in UGT1A7*2, *3, and *4. Upon functional analysis with SN-38, five out of nine UGT1A7 allozymes exhibited much lower SN-38 glucuronidation activities compared with UGT1A7*1, all having in common the mutational changes at codons 115 or 208. Results suggest that these low SN-38 glucuronidating alleles may represent additional molecular determinants of irinotecan-induced toxicity and warrant further investigations.Keywords
This publication has 34 references indexed in Scilit:
- Founder TIGR/myocilin mutations for glaucoma in the Quebec populationHuman Molecular Genetics, 2002
- Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer PatientsJapanese Journal of Cancer Research, 2002
- UDP Glucuronosyltransferase mRNA Levels in Human Liver DiseaseDrug Metabolism and Disposition, 2002
- UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityThe Pharmacogenomics Journal, 2002
- Recommendation for Caution with Irinotecan, Fluorouracil, and Leucovorin for Colorectal CancerNew England Journal of Medicine, 2001
- A New Statistical Method for Haplotype Reconstruction from Population DataAmerican Journal of Human Genetics, 2001
- Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecinXenobiotica, 2001
- Glucuronidation of 7-Ethyl-10-hydroxycamptothecin (SN-38) by the Human UDP-Glucuronosyltransferases Encoded at the UGT1 LocusBiochemical and Biophysical Research Communications, 1999
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancerThe Lancet, 1998